Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Cell Mol Biol Lett ; 22: 26, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29213292

RESUMO

BACKGROUND: Many studies have investigated the characteristics and biological activities of type III interferon (IFN), finding that it has similar features to type I IFN but also unique actions because it is recognized by a different receptor. RESULTS: A full-length recombinant human IFN-λ1 (rhIFN-λ1) cDNA was cloned into the pDF expression vector and stably expressed in Flp-In-CHO cells. After four purification steps (ammonium sulfate precipitation, SP Sepharose chromatography, Blue Sepharose 6 fast flow affinity chromatography and molecular sieve chromatography), the rhIFN-λ1 had a purity of about 90% and was found to have the predicted biological activities. The anti-viral activity of rhIFN-λ1 was determined as 106 IU/mg using the vesicular stomatitis virus (WISH-VSV) assay system. The anti-proliferation activity of rhIFN-λ1 was measured using the MTS method and the growth inhibition ratio was 57% higher than that for recombinant human IFN-α2b (rhIFN-α2b) when the rhIFN-λ1 concentration was 1000 IU/ml. rhIFN-λ1 had lower natural killer cell cytotoxicity than rhIFN-α2b. CONCLUSION: The Flp-In-CHO system is suitable for stably expressing rhIFN-λ1 that possesses the predicted anti-viral, anti-proliferation and natural killer cell cytotoxicity-promoting activities.


Assuntos
Interleucinas/metabolismo , Interleucinas/farmacologia , Animais , Antivirais/farmacologia , Células CHO , Morte Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Clonais , Cricetulus , Vetores Genéticos/metabolismo , Interferons , Interleucinas/isolamento & purificação , Células Matadoras Naturais/efeitos dos fármacos , Células Matadoras Naturais/metabolismo , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/farmacologia , Transfecção
2.
Virol J ; 12: 166, 2015 Oct 13.
Artigo em Inglês | MEDLINE | ID: mdl-26463646

RESUMO

BACKGROUND: HPyV6 is a novel human polyomavirus (HPyV), and neither its natural history nor its prevalence in human disease is well known. Therefore, the epidemiology and phylogenetic status of HPyV6 must be systematically characterized. METHODS: The VP1 gene of HPyV6 was detected with an established TaqMan real-time PCR from nasopharyngeal aspirate specimens collected from hospitalized children with respiratory tract infections. The HPyV6-positive specimens were screened for other common respiratory viruses with real-time PCR assays. RESULTS: The prevalence of HPyV6 was 1.7 % (15/887), and children ≤ 5 years of age accounted for 80 % (12/15) of cases. All 15 HPyV6-positive patients were coinfected with other respiratory viruses, of which influenza virus A (IFVA) (8/15, 53.3 %) and respiratory syncytial virus (7/15, 46.7 %) were most common. All 15 HPyV6-positive patients were diagnosed with lower respiratory tract infections, and their viral loads ranged from 1.38 to 182.42 copies/µl nasopharyngeal aspirate specimen. The most common symptoms were cough (100 %) and fever (86.7 %). The complete 4926-bp genome (BJ376 strain, GenBank accession number KM387421) was amplified and showed 100 % identity to HPyV6 strain 607a. CONCLUSIONS: The prevalence of HPyV6 was 1.7 % in nasopharyngeal aspirate specimens from hospitalized children with respiratory tract infections, as analyzed by real-time PCR. Because the coinfection rate was high and the viral load low, it was not possible to establish a correlation between HPyV6 and respiratory diseases.


Assuntos
Filogenia , Infecções por Polyomavirus/epidemiologia , Infecções por Polyomavirus/virologia , Polyomavirus/classificação , Polyomavirus/isolamento & purificação , Infecções Respiratórias/epidemiologia , Infecções Respiratórias/virologia , Adolescente , Pequim/epidemiologia , Criança , Criança Hospitalizada , Pré-Escolar , Análise por Conglomerados , DNA Viral/química , DNA Viral/genética , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Dados de Sequência Molecular , Nasofaringe/virologia , Orthomyxoviridae , Polyomavirus/genética , Prevalência , Reação em Cadeia da Polimerase em Tempo Real , Vírus Sinciciais Respiratórios , Análise de Sequência de DNA , Homologia de Sequência
3.
Virol Sin ; 36(3): 449-457, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33231856

RESUMO

Kaposi's sarcoma (KS) originates from vascular endothelial cells, with KS-associated herpesvirus (KSHV) as the etiological agent. SRY-box transcription factor 5 (SOX5) plays different roles in various types of cancer, although its role in KS remains poorly understood. In this study, we identified the role of SOX5 in KS tissues and KSHV-infected cells and elucidated the molecular mechanism. Thirty-two KS patients were enrolled in this study. Measurement of SOX5 mRNA and protein levels in human KS tissues and adjacent control tissues revealed lower levels in KS tissues, with KS patients having higher SOX5 level in the early stages of the disease compared to the later stages. And SOX5 mRNA and protein was also lower in KSHV-infected cells (iSLK-219 and iSLK-BAC) than normal cells (iSLK-Puro). Additionally, SOX5 overexpression inhibited cell proliferation and promoted apoptosis and decreased KSHV-infected cell migration and invasion. Moreover, we found that SOX5 overexpression suppressed the epithelial-to-mesenchymal transition of KSHV-infected cells. These results suggest SOX5 is a suppressor factor during KS development and a potential target for KS treatment.


Assuntos
Herpesvirus Humano 8 , Sarcoma de Kaposi , Apoptose , Proliferação de Células , Células Endoteliais , Herpesvirus Humano 8/genética , Humanos , Fatores de Transcrição SOXD
4.
Artigo em Zh | MEDLINE | ID: mdl-20066991

RESUMO

OBJECTIVE: To explore the apoptosis induced by dexamethasone and adenosine triphosphate (ATP) in protoscolex of Echinococcus granulosus. METHODS: Protoscoleces were cultured in vitro and used for the experiment in 4 groups: dexamethasone (5 mmol/L) group, ATP (1.6 mmol/L) group, dexamethasone (5 mmol/L)+ATP (1.6 mmol/L) group, and RPMI 1640 medium as control group. The morphology of protoscolex was observed by light microscopy. After drug treatment for 8 h, the group with significant morphological changes in protoscolex was selected to observe the ultrastructure of protoscolex by transmission electron microscopy. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay (TUNEL) was employed to observe the apoptosis. Caspase-3 activity was detected with a kit, and DNA fragments were seperated by agarose gel electrophoresis. RESULTS: After induced for 8 h, the protoscoleces shrank in dexamethasone group and dexamethasone+ATP group, the rostellum was invaginated. Compared with the control, the calcareous corpuscles in the protoscolex significantly reduced and blurred in the two groups The morphological changes in protoscolex of dexamethasone+ATP group was more obvious than that of dexamethasone group. Electron microscopy showed that dexamethasone+ATP-treated protoscoleces possessed typical morphological features of apoptosis, including the cell volume reduction with densified cytoplasm, cell membrane blebbing, and nuclear heterochromatin peripheral aggregation below the nuclear membrane. A few apoptotic cells were found in protoscolex of dexamethasone+ATP group by TUNEL, while none in the control. Caspase-3 activity significantly increased 12-fold compared to the control. About 150 bp DNA fragment exhibited the typical DNA ladder formation characteristic for apoptosis in dexamethasone+ATP group. CONCLUSION: Apoptosis in the protoscolex of E. granulosus may be induced by dexamethasone and ATP in vitro.


Assuntos
Trifosfato de Adenosina/farmacologia , Apoptose/efeitos dos fármacos , Dexametasona/farmacologia , Echinococcus granulosus/efeitos dos fármacos , Animais , Caspase 3/metabolismo , Células Cultivadas , Echinococcus granulosus/citologia
5.
Protein Eng Des Sel ; 31(9): 355-360, 2018 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-30496575

RESUMO

The previously generated recombinant human (rh) interferon (IFN)-λ1 protein has a short half-life, and this feature makes it challenging to conduct studies on potential clinical applications for rhIFN-λ1. In an attempt to overcome this difficulty, we constructed a 'long-life' version of rhIFN-λ1. This modified rhIFN-λ1, named rhIFN-λ1-CTPON, has a human chorionic gonadotropin ß subunit carboxyl-terminal peptide (CTP) and an N-glycosylation sequence linked to its C-terminus. We confirmed the sequence of rhIFN-λ1-CTPON by mass spectrometry and then measured its biological activities. The results show that rhIFN-λ1-CTPON had antiviral activity and anti-proliferation activity in vitro that were similar to those of rhIFN-λ1 and that it similarly promoted natural killer cell cytotoxicity. Notably, the in vivo half-life of rhIFN-λ1-CTPON was determined to be 3-fold higher than that of rhIFN-λ1. We also assessed the anti-hepatitis B virus activity of rhIFN-λ1-CTPON; it was able to inhibit the production of the antigens HBs-Ag and HBe-Ag and induce antiviral gene expression. In conclusion, rhIFN-λ1-CTPON has a longer half-life than rhIFN-λ1 and has similar biological activities, so rhIFN-λ1-CTPON is an appropriate substitute for rhIFN-λ1 in the further study of potential clinical applications for rhIFN- λ1.


Assuntos
Interferon gama/metabolismo , Interferon gama/farmacologia , Proteínas Recombinantes de Fusão/metabolismo , Proteínas Recombinantes de Fusão/farmacologia , Animais , Antivirais/metabolismo , Antivirais/farmacocinética , Antivirais/farmacologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Gonadotropina Coriônica Humana Subunidade beta/genética , Expressão Gênica/efeitos dos fármacos , Genes Virais/genética , Humanos , Interferon gama/genética , Interferon gama/farmacocinética , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/farmacocinética
6.
Artigo em Zh | MEDLINE | ID: mdl-24319953

RESUMO

OBJECTIVE: To construct the eukaryotic expression vector PCI-dhfr-lambda1 and PCI-dhfr-SP163-lambda1 which linked the enhancer SP163 with interferon lambda1. Then express the interferon lambda1 in CHO (dhfr-) cells. METHODS: Using PCR method to introduce the restriction enzyme sites and through the fusion PCR binding the enhancer with the interferon Lambda1. After sequenced, lambda1 and SP163-lambda1 was inserted into PCI-dhfr forming the expression vector PCI-dhfr-lambda1 and PCI-dhfr-SP163-lambda1 which was constructed successfully confirming by sequencing. Then the expressing vectors were transfected into CHO (dhfr-) cells using liposome transfection method and interferon lambda1 protein was assayed with indirect immunofluorescence and Western Blot. Using cytopathic effect inhibition evaluated the antiviral activity of interferon lambda1. RESULTS: Successfully constructing the eukaryotic expression vectors of interferon lambda and the vectors could express interferon lambda1. The result of immunofluorescence showed the enhancer developed the expression of interferon lambda1. Detecting the interferon lambda1 in CHO (dhfr-) cells after transfecting 48 hour using Western Blot. The cytopathic effect inhibition showed the expressed interferon lambda1 has the antiviral activity. CONCLUSION: Successfully expressed the interferon lambda1 in CHO (dhfr-) cells and the protein possesses antiviral activity, which may supply a valuable basis for building the stable cell line of interferon lambda1.


Assuntos
Interleucinas/genética , Animais , Western Blotting , Células CHO , Cricetinae , Cricetulus , Técnica Indireta de Fluorescência para Anticorpo , Interferons , Interleucinas/farmacologia , Reação em Cadeia da Polimerase , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/farmacologia , Transfecção
7.
Artigo em Zh | MEDLINE | ID: mdl-22919759

RESUMO

OBJECTIVE: To express and purify HBoV VP2 protein, and the monoclonal antibody against HBoV VP2 protein was prepared with hybridoma technique. METHODS: The HBoV VP2 cloned into vector pET-30a was expressed in E. coil. After purified by immobilized metal affinity chromatography, the BALB/c mouse was immunized with purified protein as antigen. The positive hybridoma cells were screened with hybridoma technique and ELISA assay. Isotype and titer of the monoclonal antibody were detected. RESULTS: The recombinant HBoV VP2 protein was expressed and purified, and then the monoclonal antibody was obtained with hybridoma technique. The titer of the IgG monoclonal antibody was up to 1:4 x 10(5). CONCLUSION: Monoclonal antibody against recombinant HBoV VP2 protein was prepared and the antibody titer was high. This work may provide a new method in rapid diagnosis and study of HBoV.


Assuntos
Anticorpos Monoclonais/imunologia , Proteínas do Capsídeo/imunologia , Bocavirus Humano/imunologia , Animais , Proteínas do Capsídeo/genética , Hibridomas , Camundongos , Camundongos Endogâmicos BALB C , Plasmídeos , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA